NNSA Signs Cooperative Agreement to Produce Molybdenum-99 in the United States without the use of Highly Enriched Uranium

National Nuclear Security Administration (NNSA)
Published: November 1, 2011

WASHINGTON, D.C. – The National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative announced today the signing of a cooperative agreement with NorthStar Medical Radioisotopes, LLC, to further the development of accelerator-based technology to produce molybdenum-99 (Mo-99) in the United States. 

The cooperative agreement between NNSA and NorthStar, which totals $4.6 million and is funded under a 50 percent/50 percent cost-share arrangement, will accelerate the development of the NorthStar technology to produce Mo-99 without proliferation-sensitive highly enriched uranium (HEU). The agreement would also support the goal of ensuring a reliable domestic supply of this critical medical isotope for U.S. patients.

The United States currently does not have a domestic production capability for Mo-99 and must import 100 percent of its supply from foreign producers, most of which use HEU in their production processes.  Over the past few years, technical difficulties and shutdowns at the major Mo-99 production facilities have caused severe supply shortages, which have greatly impacted the availability of Mo-99 to the medical community. The Mo-99 produced by NorthStar would provide additional reliability for the U.S. supply.

As part of its nuclear nonproliferation mission, NNSA works to accelerate the establishment of a diverse, reliable supply of the critical medical isotope Mo-99, produced without the use of HEU, and this agreement is a significant step in those efforts.  

“NNSA is committed to supporting a diverse set of technologies for the establishment of a reliable supply of molybdenum-99 produced here in the United States without the use of highly enriched uranium,” said Deputy Administrator for Defense Nuclear Nonproliferation Anne Harrington. “We are committed to supporting the technical advancement of commercial partners to meet the needs of the U.S. medical community while simultaneously advancing nonproliferation objectives and the minimization of civilian use of HEU worldwide.”

NNSA has partnered with four domestic commercial entities to accelerate the establishment of a diverse, reliable supply of Mo-99 within the United States that is not produced with HEU. NNSA also works with international producers to assist in the conversion of their Mo-99 production facilities from the use of HEU targets to LEU targets. These efforts are part of NNSA’s Global Threat Reduction Initiative’s mission to minimize and, to the extent possible, eliminate the use of HEU in civilian applications worldwide, including in research reactors and medical isotope production facilities. 

For more information on NNSA’s efforts to establish a reliable supply of Mo-99 without the use of HEU, click here.

Follow NNSA News onFacebook, Twitter, YouTube, and Flickr.

Established by Congress in 2000, NNSA is a semi-autonomous agency within the U.S. Department of Energy responsible for enhancing national security through the military application of nuclear science. NNSA maintains and enhances the safety, security, reliability and performance of the U.S. nuclear weapons stockpile without nuclear testing; works to reduce global danger from weapons of mass destruction; provides the U.S. Navy with safe and effective nuclear propulsion; and responds to nuclear and radiological emergencies in the United States and abroad.